This is absolutely true. The FDA knows what it's doing, and you can be sure it despises SRPT investors given all the hate mail so many of sent in the past few years.
20-day moving average and 50% Fib retrace from March lows. Either one of these by itself is good support, but together much better.
So you want management to play the role of a pumper?
Also, dropping from $26-$17 in a week isn't a slow bleed.
Lastly, you should have added today. $17 is major support and will probably not be breached.
Historically, the answer to your question is no, at least if you are thinking in terms of bullish bets. However, there were some bullish options bets at the beginning of 2015 that did foretell the future. But those are the only ones I can recall in the past few years.
[leak via twitter via quality contributor]
COMPLETELY FALSE. No such thing is on twitter. A sarcastic comment suggesting your scenario, but it was sarcastic.
Yeah, pretty heavy flow out there. Someone is throwing down a lot of money thinking eteplirsen is given a positive review and subsequent approval.
Not that it's a reason to play long. I own no stock currently. Just some January 2017 $10 and $15 calls that I bought in March 2015, and I'm riding freebies with those.
I get your point, but I doubt the stock will be trading at $21 by the time the docs are released. I imagine there will be a little more decline by next Friday as traders play it safe. My main point is that if BDs are more or less the same, the stock probably isn't dropping back to $10.
True enough. How much would book value play into a leveraged buyout? Because the premium here could be quite large if TLN is taken out.
The assumption by most is that they aren't going to be materially different from the previous batch. Thus, do not expect a huge dump if that is the case. Good chance it'll be priced in. Not completely, but we won't see the stock ripped in half again. On the other hand, any whiff of positivity could pop the stock quite nicely. Remember, there was absolutely none last time.